SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Veteran98 who wrote (49650)7/20/2000 10:16:28 AM
From: SSP  Read Replies (1) of 150070
 
ZKEM, still going!

 Xechem International       Ticker: ZKEM                     Page 1 of 10        
Complete Financials: March 2000            Exchange  OTC                        
                                           FY END DEC                           
    ISSUE DATA (07/14/00)      PER SHARE DATA               RATIOS              
Price    $     0.08      EPS (TTM)  $    -0.01   P/E (TTM)          NM          
52W High $     1.00      Div. Rate  $     0.00   Yield            0.00 %        
52W Low  $     0.03      Book Value $     0.00   Price/Book         NM          
Shrs Out     240.85 Mil  Cash       $     0.00   ROE (TTM)   -1,177.93 %        
Float         98.70 Mil  Rev (TTM)  $     0.00   ROA (TTM)     -135.74 %        
Mon. Vol       4.55 Mil                          Curr. Ratio      0.24          
Beta          -1.25                              LT Dbt/Eqty        NM          
     BRIEF:  Xechem International is a development stage                        
     bio-pharmaceutical company currently engaged in research,                  
     development and the limited production of niche generic and                
     proprietary drugs from natural sources.  For the 3 months                  
     ended 3/31/00, revenues fell 22% to $7K.  Net loss rose 30%                
     to $359K.  Revenues reflect a decrease in product sales by                 
     the XetaPharm subsidiary.  Loss also reflects increased                    
     legal fees and research and development expenses.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News